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Background. Congenital cytomegalovirus (CMV) infection is the most prevalent congenital infection worldwide. Epidemiology
and clinical outcomes are known to vary with socio-economic background, but few data are available from developing
countries, where the overall burden of infectious diseases is frequently high. Methodology/Principal Findings. As part of an
ongoing birth cohort study in The Gambia among term infants, urine samples were collected at birth and tested by PCR for the
presence of CMV DNA. Risk factors for transmission and clinical outcome were assessed, including placental malaria infection.
Babies were followed up at home monthly for morbidity and anthropometry, and at one year of age a clinical evaluation was
performed. The prevalence of congenital CMV infection was 5.4% (40/741). A higher prevalence of hepatomegaly was the only
significant clinical difference at birth. Congenitally infected children were more often first born babies (adjusted odds ratio
(OR) 5.3, 95% confidence interval (CI) 2.0-13.7), more frequently born in crowded compounds (adjusted OR 2.9, 95%CI 1.0-8.3)
and active placental malaria was more prevalent (adjusted OR 2.9, 95%CI 1.0-8.4). These associations were corrected for
maternal age, bed net use and season of birth. During the first year of follow up, mothers of congenitally infected children
reported more health complaints for their child. Conclusions/Significance. In this study, the prevalence of congenital CMV
among healthy neonates was much higher than previously reported in industrialised countries, and was associated with active
placental malaria infection. There were no obvious clinical implications during the first year of life. The effect of early life CMV
on the developing infant in the Gambia could be mitigated by environmental factors, such as the high burden of other
infections.
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INTRODUCTION
Congenital cytomegalovirus (CMV) infection is the most prevalent
congenital infection worldwide, with recent estimates ranging from
0.1–2% of all pregnancies being affected [1–4]. Infection-in-utero
is potentially fatal to the foetus, and is associated with a range of
adverse outcomes involving multiple organs, in particular the liver
and the central nervous system. Of those born with congenital
infection, up to 10% of infected foetuses have mild or severe
disease. Neonatal mortality associated with symptomatic congen-
ital CMV infection during the first year of life is estimated to be
over 10% [5]. The majority of those with a congenital infection
are however asymptomatic at birth. Of those born without obvious
clinical symptoms, another 10% may suffer from long-term
sequelae, in particular audito-neurological complications, with
hearing loss being the most prevalent [6,7].
Congenital CMV infection occurs through vertical transmission
of the virus by an infected pregnant woman to the foetus via the
placenta. This may arise through primary infection of the mother,
reactivation during pregnancy of a latent infection or re-infection
with a different strain of CMV [8]. The incubation period of the
infection is about 2–3 weeks, after which shedding of the virus can
be detected in secretions such as urine, vaginal secretions and
breast milk [9]. Transmission occurs through shedding of the virus
in body fluids during such periods of active replication, although
the mechanisms involved in transplacental transfer remain poorly
understood [10,11]. In the industrialised world, where prevalence
rates among young adults are estimated to be around 40–50%,
congenital infection usually occurs following a primary infection of
the mother during pregnancy [12]. Such a primary infection is
estimated to occur in 1–4% of pregnancies, 20 to 40% of which
subsequently result in transmission of CMV to the foetus. Clinical
symptoms tend to be less severe among children infected following
reactivation of the virus during pregnancy. Nevertheless, recent
data from industrialised countries suggest that congenital infec-
tions following recurrent maternal infections may represent
a significant proportion of the disease burden associated with
congenital CMV infection [13,14].
CMV infection has a profound impact on the immune system
by decreasing cell-mediated immune responses during the early
phase of the infection and by promoting immune ageing [15,16].
We have shown that CMV infection in early life induces a large
subset of T lymphocytes expressing a late differentiation
phenotype [17], that is associated with immunosenescence in the
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only lead directly to increased morbidity at birth and during the
early years, but could also impact indirectly on the health of an
infected child through immunosuppression. This could interfere
with a robust response on the routine infant vaccinations, and with
the response to other infections.
Clinical and epidemiological patterns of CMV infection are
known to differ according to socio-economic and geographical
settings, although there are limited data from developing
countries. We studied the incidence and clinical sequelae of
congenital CMV within a peri-urban birth cohort, and explored
the impact of a range of risk factors (placental malaria, CMV viral
load, maternal and infant demographics) on placental transmission
and clinical outcome. We hypothesised that placental malaria and
CMV maternal viral load would contribute to the risk of
congenital infection, and that apparently asymptomatic infection
might still affect the clinical development and health of the infants.
We here report on risk factors for congenital CMV infection in
a highly endemic region and the clinical impact of a congenital
infection observed during the first year of life in a cohort of term,
healthy, babies in The Gambia.
METHODS
Subjects
In January 2002, a birth cohort was initiated in the village of
Sukuta, The Gambia, approximately 15 km away from the
Medical Research Council (MRC) Laboratories in Fajara, in
order to study the epidemiological, clinical, immunological and
virological determinants of early life CMV infection in an endemic
environment. The wider objective of this cohort was to understand
how the immune system of the foetus and new born develops in
relation to CMV and other early life infections, and how this
interacts with the response to vaccinations.
Sukuta has approximately 25,000 inhabitants, and is adjacent to,
but distinct from the nearby expanding peri-urban community
centred around the village of Serrekunda between the capital Banjul
20 km to the north and a growing urban centre (Brikama) 25 km to
the south. A variety of ethnic groups live in the village, although the
Mandinka group make up about half of the population.
Eligible for recruitment in the cohort were children born in the
health centre of the study village whose parents gave informed
consent. Babies whose mothers had suffered a serious infectious
diseaseduringpregnancyforwhichtheyhadbeenadmittedwerenot
recruited. Pre-term babies, babies born with a serious congenital
deficit, or babies whowere in need for a transfer toa referral hospital
immediately following delivery, were not included either. Routine
follow up was conducted monthly. During these routine visits,
anthropometric measurements and a morbidity checklist were
completed. Vaccinations were given according to the Gambia
Government schedule. Recruitment and follow-up are still ongoing.
Laboratory investigations
a. CMV Urine was collected within two weeks of birth and
transported to the laboratory within 24 hours, and stored at
220uC. CMV DNA was detected by an in-house nested PCR
method amplifying a region of the UL50 gene. Frequent negative
controls (one in seven reactions) were included to minimise the risk
of false-positive reactions. CMV viral load in maternal samples
collected at the time of delivery (vagina, urine, saliva, colostrum
and plasma) from a sub-set of mothers was quantified by real-time
PCR. The lower limit of detection by real-time PCR was 100
copies/ml for plasma and vaginal swab, and 50 copies/ml for the
other samples. Maternal plasma levels of CMV-specific IgG were
detected and quantified using commercial enzyme immunoassays
(DiaSorin, Saluggia, Italy) used according to the manufacturer’s
instructions. The complete results from maternal testing will be
described in a subsequent viroimmunology paper.
b. Placental malaria Immediately upon delivery, a placental
imprint was made on a glass slide. Slides were Giemsa stained, and
transported to the laboratory for the detection of parasitaemia.
Slides were read by a trained microscopist for the speciation and
quantification of malaria parasites; and a random selection of
slides was read by a second trained microscopist to assure quality
control. At least 100 fields were read before a negative result was
declared. A placental biopsy was taken and immediately placed
into 10% formalin for transport to the laboratory. Each placental
sample was embedded in paraffin wax, sectioned and stained with
standard H&E stain. Slides were examined under a light
microscope for evidence of malaria infection according to the
classification described by Ismail et al. [20]. Thus placentas were
ascribed to one of 4 groups: no infection, acute infection (parasites
in the intervillous space), chronic infection (parasites and malaria
pigment) or past infection (pigment only).
Clinical evaluation
A paediatric assessment, including a neurological examination of
the child was performed at birth by a qualified paediatrician (first
OO, later MP), at which time the CMV status of the baby was not
yet known. Baseline data were collected at birth, and every month,
morbidity data and anthropometry was collected in a standardised
way. Parents could consult the paediatrician with any complaints
or concerns about their children’s health and welfare throughout
the follow up period, and at one year of age another standardised
clinical evaluation was performed by the paediatrician. Maternal
height and weight were measured six months after delivery.
Definitions
Congenital CMV was defined as the detection of CMV in the urine
by PCR within two weeks of birth. Acute malaria infection was
defined as the detection of malaria parasites by microscopy, or the
detection of an acute infection by histology. Active malaria infection
was defined as a histological diagnosis of acute or chronic infection.
Analysis
Field, clinic and laboratory data were all merged and validated in
a relational Microsoft Access database. Data were analysed using
Stata 8 (Stata Corp, Texas, USA). Statistical significance was
assigned when a p-value,0.05 was obtained. Differences in
proportions were compared with a chi-squared test. Univariate
logistic regression analysis was used to calculate odds ratio’s (ORs) to
test for significance of associations between risk factors and
congenital CMV infection. Where needed, variables were dichot-
omised or categorised to enable inclusion in a logistic regression
analysis. Risk factors were included in a stepwise backward
multivariate model if p,0.1 to obtain independent adjusted ORs.
Ethics
The study was approved by the Gambia Government/MRC
Ethics Committee. All parents gave written informed consent for
their child to participate.
RESULTS
Subjects
Between January 2002 and January 2005, 840 eligible babies were
recruited into the cohort. Urine was collected within the first two
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PLoS ONE | www.plosone.org 2 June 2007 | Issue 6 | e492weeks of life from 741 of them (88.2%), and congenital CMV was
diagnosed in 40/741 newborns (5.4%). The prevalence of
congenital infection was higher among first born babies (11.2%
vs 3.8%, p-value,0.001). If a baby was not a mother’s first child,
then congenital infection was associated with being born into
a larger family (4.1 older siblings vs 3.1, p-value=0.04). Although
not statistically significant, babies with CMV were born into
slightly more populated compounds (table 1).
At Birth
Among the congenitally infected group, the prevalence of first
pregnancies was significantly higher (50% vs 21%, p,0.001).
There was no seasonal variation in the detection of congenital
CMV infection, but the prevalence of placental parasitaemia was
significantly higher among cases of congenital CMV (26% vs 11%,
p-value=0.03), The prevalence of all histologically confirmed
malaria was not significantly increased (17% vs 12%, p-
value=0.4). Primiparity (OR 5.3, 95%CI 2.0-13.7), crowding in
the compound (defined as living with 13 people or more) (OR 2.9;
95%CI 1.0-8.3), and acute malaria (OR 2.9; 95%CI 1.0-8.4) were
found to be independently associated with congenital infection in
a multivariable logistic regression (table 2). There were no
independent associations between congenital CMV infection and
season of birth, maternal age, bednet use, sex of the baby, or
maternal body mass index.
Sero-prevalence of CMV infection was assessed at time of
delivery among 194 of the mothers of a recruited newborn. All
women (100%) had detectable CMV IgG. CMV viral load at the
time of delivery was assessed in a subset of 84 mothers, of whom
11 (13.1%) gave birth to a baby with congenital CMV infection.
The geometric mean titre (GMT) of the CMV viral load was
significantly higher in colostrum (4220 vs 167, p-value=0.001) in
mothers who gave birth to congenitally infected babies, the GMT
was borderline significantly higher in vaginal fluids (6000 vs 1107,
p-value=0.05) and not significantly higher in saliva (536 vs 118, p-
value=0.1). There was no association between the GMT of CMV
viral load and placental malaria (p-value=0.6 for the association
of active placental malaria with GMT vaginal fluid, p-value=0.1
with GMT colostrum).
There were no significant differences in clinical evaluation post-
partum between the two groups, except for a higher prevalence of
hepatomegaly among congenitally infected infants (2.5% vs 0.3%,
p-value=0.03) (table 3). There were no other significant differ-
ences apparent at birth, such as in maternal characteristics, sex,
birth weight, placental weight, developmental or Apgar score
between those with and those without congenital CMV.
Follow up
After the first year of follow up, 13 (1.8%) of the children had died
(none of them congenitally infected, p=0.4), and 66 (8.9%; one of
the 40 congenitally infected children, p=0.1) were lost to follow
up, leaving 662 children eligible for clinical and neurological
assessment at one year of age. Of these children, the outcome after
one year was assessed for 543 children (82.0%) (table 4).
During the first year of their life, 8961 follow-up visits to the
clinic were made (median of 8 visits per child, range 1–25) during
each of which growth and morbidity were routinely monitored.
During nearly half of these visits, the mother or caregiver reported
some health complaint of the child. Mothers of congenitally
infected children reported complaints at 53.4% of the visits
compared to 46.6% of visits for those that were not congenitally
infected (p-value=0.04). At one year of age, 30/40 (75.0%) of the
congenitally infected and 512/701 (73.0%) of non-congenitally
Table 1. Background characteristics of babies born with and
without congenital CMV infection recruited January 2002 to
January 2005.
......................................................................
Congenital
CMV infection
No congenital
CMV infection p-value
N 40 (5.4) 701 (94.6)
n (%) females 20 (50.0) 330 (47.1) 0.7
Maternal age (yrs, median, IQR) 23 (20–30) 25 (21–30) 0.3
Maternal body mass index
(m
2/(kg) (mean, sd)
21.5 (4.8) 22.2 (4.1) 0.5
n (%) first pregnancy 18 (46.2) 143 (20.5) ,0.001
If not first child:
number of elder siblings alive
(mean, sd)
3.6 (2.5) 2.7 (1.8) 0.02
n/N (%) where elder sib died 9/22 (40.9) 166/551 (32.0) 0.4
People living in same compound
(median, IQR)
16 (10–26) 13 (8–20) 0.1
Placental parasitaemia (n/N, %) 6/24 (25.0) 50/445 (11.2) 0.04
Acute placental malaria infection
(n/N, %)
7/23(30.4) 63/413 (15.3) 0.05
Born in malaria/hungry [41]
season (August-December)
(n, %)
16 (40.0) 326 (46.5) 0.4
IQR=inter quartile range; sd=standard deviation
doi:10.1371/journal.pone.0000492.t001
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Table 2. Independent risk factors (OR, 95% CI) for congenital
CMV infection
......................................................................
Crude OR Adjusted OR
Primiparity 3.2 (1.7–6.1) 5.3 (2.0–13.7)
Crowding in compound 1.7 (0.8–3.4) 2.9 (1.0–8.3)
Acute placental malaria 2.4 (1.0–6.1) 2.9 (1.0–8.4)
doi:10.1371/journal.pone.0000492.t002
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Table 3. Clinical characteristics at birth of children with and
without congenital CMV infection.
......................................................................
Congenital
CMV infection
No congenital
CMV infection p-value
N (%) 40 (5.4) 701 (94.6)
Jaundice (n, %) 2 (5.0) 14 (2.0) 0.2
Purpura (n, %) 3 (7.5) 46 (6.7) 0.9
Hepatomegaly (n, %) 1 (2.5) 2 (0.3) 0.03
Cardiac murmur (n, %) 0 2 (0.3) 0.7
Neurological score (mean, sd)* 30.6 (2.0) 30.8 (1.8) 0.5
Birth weight (mean, sd) 3058 (489) 3030 (444) 0.7
Birth length (mean, sd) 48.8 (1.9) 48.6 (2.7) 0.6
Head circumference (mean, sd) 34.0 (1.2) 33.8 (2.1) 0.7
Placental weight (mean, sd) 578 (122) 561 (126) 0.4
Apgar (median, IQR) 9 (9–10) 9 (9–10) 0.9
IQR=inter quartile range; sd=standard deviation
Neurological score following Dubrovnivc: maximum score=35
doi:10.1371/journal.pone.0000492.t003
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assessment. No significant differences in developmental, clinical or
anthropometricobservationswereobservedbetweenthe two groups.
DISCUSSION
Our data showed that nearly one in every twenty live-born
newborns in the study area was congenitally infected with CMV.
This is likely to be an underestimate of the actual incidence in the
community since children with a low birth weight were initially not
included, and some children who were born very ill may have
been referred immediately upon delivery and could therefore not
be asked to participate in the cohort. Both outcomes may have
been associated with congenital CMV infection resulting in an
underestimate of the incidence of congenital CMV infection. This
prevalence is higher than reported in most other studies, but is
consistent with a previous study in The Gambia [21]. This higher
prevalence could therefore be related to a higher risk of infection,
but it may also be related to under diagnosis in other areas if less
sensitive diagnostic methods such as virus culture were used.
No clinical congenital CMV syndrome was observed at birth,
and no significant differences in the prevalence of symptoms at
birth between those with and without congenital CMV infection.
Because recruitment and assessment of CMV status was done at
the time of delivery only, no information on (infected) stillbirths is
available. This, and the fact that babies who needed an immediate
transfer to the referral hospital due to prematurity or serious
morbidity were not included either, means that we may have
underestimated the clinical impact of congenital CMV infection. A
study in Brasil in an area also with a high population CMV
seroprevalence observed a similar prevalence of congenital
infection in full-term and pre-term babies, with no symptomatic
babies among the term-babies, while the majority of the infected
pre-term infants were symptomatic [22]. In this cohort, seropre-
valence among the subgroup of women assessed at the time of
delivery was 100%, which is similar to the seroprevalence found
among a group of 93 Gambian children aged 4–5 year old living
in the same area (unpublished data). Therefore, it seems highly
likely that all or nearly all of the pregnant women will have been
infected with CMV prior to the pregnancy, and that most or all of
the congenital infections will have resulted from recurrent maternal
infection, either through reactivation or reinfection, which is likely to
be less severe than infection following a maternal primo-infection
[12]. It is also possible that due to high pressure of competing
infections [23] non-specific immune factors are stimulated which
could contribute to protective immunity. Also, as exposure of the
mothers to CMV is high, their natural immunity and control of
CMV replication if infected could be better. The significant
association of a high maternal viral load with congenital infection
indicates that generalised active maternal viral shedding around the
time of delivery is related to the risk of the infant becoming infected.
Further studies of immune responses to congenital and post-natal
CMV infection in this cohort are ongoing.
The finding that the prevalence of placental malaria was higher
in congenitally infected infants confirmed our initial hypothesis. We
have previously shown that placental infection with P. falciparum
affects Th1 differentiation of cord blood T lymphocytes [24] and it
has been shown before that malaria infection can suppress immunity
to a variety of viral infections, such as HIV, Epstein Barr virus,
vaccinia and lymphocytic choriomeningitis virus [25,26,27]. The
production of specific immune factors could inhibit the control of
CMV and promote apoptosis of trophoblasts which would facilitate
transplacental transfer of CMV, once infection of the cytotropho-
blast has occurred [10], and it is possible that placental malaria
infection stimulates a similar mechanism leading to an increased
transmission. It is also possible that following intrauterine CMV
infection, the susceptibility of the placenta to become infected with
malaria is increased. Further investigation of this association and
possible biological mechanisms involved could give more insights in
our understanding of risk factors for congenital infections and could
guide interventions to prevent this. An association between placental
malaria and primiparity has been found before, which could be
associated with a different immune response in primiparous women
compared to multiparous women. Perhaps similar mechanisms are
involved inthe association between placental malaria and congenital
infection, as placental malaria was not, and congenital CMV
infection was associated with maternal shedding of CMV [28,29].
We did not assess the HIV status of mothers or babies, since it
was considered that stigma still surrounding HIV testing and sero-
status would have compromised willingness to participate in the
study. Among babies exposed to HIV perinatally, congenital
CMV is more common among those who became HIV infected
themselves [30]. Co-infection with HIV and CMV was associated
with greater immunosuppression and a more rapid clinical
progression compared to children infected with HIV only [31].
HIV-1 prevalence among pregnant women in The Gambia is
estimated to be around 1.0% and HIV-2 at 0.8% [32]. A previous
study from Brasil in a highly endemic CMV area reported similar
congenital CMV prevalences in HIV infected and uninfected
mothers [33]. Thus, it seems unlikely the lack of these data will
have biased our results on transmission risks and outcome. We
could not confirm previous reports which found an increased risk
for females versus males for adverse outcome following congenital
CMV infection [34].
The prevalence of reported morbidity during follow-up tended
to be higher in the congenitally infected group, but this did not
reach statistical significance. It is clear from this study that in spite
of ongoing urbanisation, and increasing availability of health
Table 4. Clinical characteristics of children with and without
congenital CMV infection who already reached one year of
age.
......................................................................
Congenitally
CMV infected
Not congenitally
CMV infected p-value
N4 0 7 0 1
Routine follow up visits during
first year of life (N)
440 8521
Symptoms reported during
monthly follow-up:
All (%) 53.4 46.6 0.04
Fevers (%) 20.9 18.7 0.2
Cough (%) 16.1 14.7 0.4
Skin problems (%) 9.5 8.9 0.7
Vomiting (%) 5.6 4.4 0.2
Diarrhoea (%) 5.4 5.7 0.8
Died during first year of life
(n, %)
0 13 (1.9) 0.4
Lost to follow up (n, %) 1 (2.5) 65 (9.3) 0.1
Available for clinical evaluation
at 1 year of age (n, %)
30 (75) 513 (73) 0.9
Weight gain (kg) at 1 year
(mean, sd)
5.6 (1.2) 5.7 (1.1) 0.8
Length gain (cm) at 1 year
(mean, sd)
24.4 (2.8) 25.1 (2.7) 0.2
doi:10.1371/journal.pone.0000492.t004
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PLoS ONE | www.plosone.org 4 June 2007 | Issue 6 | e492facilities, the burden of illness among infants and young children in
developing countries remains very high. At nearly half of all
routine visits at home, one or more complaints were reported. The
relatively low mortality amongst the infants is in stark contrast to
the high percentage of mothers who reported the death of
a previous child, and might be associated with a study bias due to
the close follow up and continuous medical care offered by the
study team. Although mothers of congenitally infected children
tended to report slightly more complaints, this was only of
borderline significance. A previous study among immunocompe-
tent patients infected with CMV also found a high proportion of
general malaise complaints rather than any specific clinical
correlates [35]. Hearing loss, often progressive, may be the only
specific complication among those with an asymptomatic
congenital infection [36]. It is possible that if we had been in
a position to use advanced electronic stimulations methods for
detecting early hearing loss, such as auditory brainstem response
or otoacoustic emissions, we would have been able to assess if any
early hearing loss differences existed (37). The mean age at which
hearing loss is diagnosed among congenitally infected children
following a non-primary infection of the mother was estimated at
39 months [38]. Continued follow up of this cohort is needed to
find out whether or not a specific clinical impact becomes
apparent around four to five years of age when a comprehensive
neurological and auditory examination is planned. Nevertheless, it
is also possible that we did not observe major differences in
outcome during the first year of life for children born with
a congenital CMV infection. This could be due to the fact that
other environmental factors, and/or other early life infections had
a much larger impact on health in this resource-poor, semi-urban,
community, which obscured more modest effects of the congenital
infection; or through interaction did not reflect in the overall
outcome indicators so far.
In recent years, antiviral therapy has become available to
mitigate the risk of clinical complications following congenital
CMV infections [39], but apart from the serious potential side
effects, this option may not be affordable to populations in low
income countries. In the long run, a (maternal) vaccine which
protects against primary and recurrent disease will be a better and
more affordable option to reduce the morbidity associated with
congenital CMV infection [40]. In the mean time, improved
understanding of risk factors associated with congenital infection
and with adverse outcome following infection is needed in order to
develop and test effective interventions.
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